Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at Netflix, Nucor, BioMarin Pharmaceutical, and Transocean.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
Netflix gets upgraded by Goldman Sachs
Goldman Sachs upgraded Netflix (NASDAQ:NFLX) to Neutral from Sell and raised its price target to $400.00 from $230.00 to reflect the overall positive current operating performance and continued forward positive operating momentum into 2024/2025 on the back of the company's global password and ad tier initiatives.
Netflix will report Q2/23 earnings on July 19. Goldman Sachs expects strong subscriber performance due to solid content, improved password crackdown, and increased revenue from unpaid users converting to paid memberships.
Shares gained more than 1% premarket today.
Nucor upgraded to Outperform
Exane BNP Paribas upgraded Nucor (NYSE:NUE) to Outperform from Neutral with a price target of $191.00, as reported in real time on InvestingPro.
The company is set to report its Q2/23 earnings on July 25. Street estimates stand at $5.39 for EPS and $9.61 billion for revenues.
2 more upgrades
BioMarin Pharmaceutical (NASDAQ:BMRN) shares rose more than 1% premarket today after BMO Capital upgraded the company to Outperform from Market Perform with a price target of $102.00.
The firm expects Biomarin's base business to provide downside protection while positive updates around Voxzogo growth and Roctavian dosing will drive upside.
Citi upgraded Transocean (NYSE:RIG) to Buy from Neutral and raised its price target to $9.50 from $6.50. Shares rose more than 1% premarket today.
Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.
Start your free 7-day trial now.
